126 related articles for article (PubMed ID: 11721160)
1. Neuraminidase treatment abrogates the binding abnormality of IgA1 from IgA nephropathy patients and the differential charge distribution of its alpha-heavy chains.
Hashim OH; Shuib AS; Chua CT
Nephron; 2001 Dec; 89(4):422-5. PubMed ID: 11721160
[TBL] [Abstract][Full Text] [Related]
2. The interaction of selective plant lectins with neuraminidase-treated and untreated IgA1 from the sera of IgA nephropathy patients.
Hashim OH; Shuib AS; Chua CT
Immunol Invest; 2001 Feb; 30(1):21-31. PubMed ID: 11419909
[TBL] [Abstract][Full Text] [Related]
3. Glycosylation profile of differently charged IgA1 and their binding characteristics to cultured mesangial cells in IgA nephropathy.
Leung JC; Chan LY; Tang SC; Tam PC; Fenn J; Lai KN
Nephron Exp Nephrol; 2007; 107(3):e107-18. PubMed ID: 17957128
[TBL] [Abstract][Full Text] [Related]
4. Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis.
Allen AC; Bailey EM; Barratt J; Buck KS; Feehally J
J Am Soc Nephrol; 1999 Aug; 10(8):1763-71. PubMed ID: 10446944
[TBL] [Abstract][Full Text] [Related]
5. Differential glycosylation of polymeric and monomeric IgA: a possible role in glomerular inflammation in IgA nephropathy.
Oortwijn BD; Roos A; Royle L; van Gijlswijk-Janssen DJ; Faber-Krol MC; Eijgenraam JW; Dwek RA; Daha MR; Rudd PM; van Kooten C
J Am Soc Nephrol; 2006 Dec; 17(12):3529-39. PubMed ID: 17050773
[TBL] [Abstract][Full Text] [Related]
6. Enzymatic sialylation of IgA1 O-glycans: implications for studies of IgA nephropathy.
Takahashi K; Raska M; Stuchlova Horynova M; Hall SD; Poulsen K; Kilian M; Hiki Y; Yuzawa Y; Moldoveanu Z; Julian BA; Renfrow MB; Novak J
PLoS One; 2014; 9(2):e99026. PubMed ID: 24918438
[TBL] [Abstract][Full Text] [Related]
7. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy.
Xu LX; Zhao MH
Kidney Int; 2005 Jul; 68(1):167-72. PubMed ID: 15954905
[TBL] [Abstract][Full Text] [Related]
8. Association of asialo-galactosyl beta 1-3N-acetylgalactosamine on the hinge with a conformational instability of Jacalin-reactive immunoglobulin A1 in immunoglobulin A nephropathy.
Hiki Y; Iwase H; Kokubo T; Horii A; Tanaka A; Nishikido J; Hotta K; Kobayashi Y
J Am Soc Nephrol; 1996 Jun; 7(6):955-60. PubMed ID: 8793806
[TBL] [Abstract][Full Text] [Related]
9. The glycans deficiencies of macromolecular IgA1 is a contributory factor of variable pathological phenotypes of IgA nephropathy.
Xu LX; Yan Y; Zhang JJ; Zhang Y; Zhao MH
Clin Exp Immunol; 2005 Dec; 142(3):569-75. PubMed ID: 16297170
[TBL] [Abstract][Full Text] [Related]
10. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG.
Tomana M; Matousovic K; Julian BA; Radl J; Konecny K; Mestecky J
Kidney Int; 1997 Aug; 52(2):509-16. PubMed ID: 9264010
[TBL] [Abstract][Full Text] [Related]
11. Detection of enriched Thomsen-Friedenrich antigen on IgA1 from IgA nephropathy patients.
Iwase H; Katsumata T; Itoh A; Hiki Y; Ikuko N; Sano T; Takatani T; Kobayashi Y
J Nephrol; 2002; 15(6):703-8. PubMed ID: 12495288
[TBL] [Abstract][Full Text] [Related]
12. Aberrant glycosylation of IgA from patients with IgA nephropathy.
Baharaki D; Dueymes M; Perrichot R; Basset C; Le Corre R; Clèdes J; Youinou P
Glycoconj J; 1996 Aug; 13(4):505-11. PubMed ID: 8872105
[TBL] [Abstract][Full Text] [Related]
13. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels.
Moldoveanu Z; Wyatt RJ; Lee JY; Tomana M; Julian BA; Mestecky J; Huang WQ; Anreddy SR; Hall S; Hastings MC; Lau KK; Cook WJ; Novak J
Kidney Int; 2007 Jun; 71(11):1148-54. PubMed ID: 17342176
[TBL] [Abstract][Full Text] [Related]
14. Mass spectrometry analysis of IgA1 hinge region in patients with IgA nephropathy.
Gastaldi D; Paradisi L; Baiocchi C; Medana C; Lo Duca G; Sena LM; Roccatello D
J Nephrol; 2007; 20(6):689-95. PubMed ID: 18046671
[TBL] [Abstract][Full Text] [Related]
15. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy.
Allen AC; Harper SJ; Feehally J
Clin Exp Immunol; 1995 Jun; 100(3):470-4. PubMed ID: 7774058
[TBL] [Abstract][Full Text] [Related]
16. Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteins.
Moore JS; Kulhavy R; Tomana M; Moldoveanu Z; Suzuki H; Brown R; Hall S; Kilian M; Poulsen K; Mestecky J; Julian BA; Novak J
Mol Immunol; 2007 Apr; 44(10):2598-604. PubMed ID: 17275907
[TBL] [Abstract][Full Text] [Related]
17. Binding capacity of in vitro deglycosylated IgA1 to human mesangial cells.
Zhang JJ; Xu LX; Zhang Y; Zhao MH
Clin Immunol; 2006 Apr; 119(1):103-9. PubMed ID: 16442846
[TBL] [Abstract][Full Text] [Related]
18. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy.
Mestecky J; Tomana M; Crowley-Nowick PA; Moldoveanu Z; Julian BA; Jackson S
Contrib Nephrol; 1993; 104():172-82. PubMed ID: 8325028
[No Abstract] [Full Text] [Related]
19. [IgA1 aberrant glycosylation in the pathogenesis of IgA nephropathy: an overivew].
Xie L; Wang L; Huang J; Fan J
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Feb; 27(1):227-30. PubMed ID: 20337060
[TBL] [Abstract][Full Text] [Related]
20. Self-aggregated deglycosylated IgA1 with or without IgG were associated with the development of IgA nephropathy.
Yan Y; Xu LX; Zhang JJ; Zhang Y; Zhao MH
Clin Exp Immunol; 2006 Apr; 144(1):17-24. PubMed ID: 16542360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
